IMM 1.49% 34.0¢ immutep limited

prr mentioned with dndn in usa news release

  1. 978 Posts.
    This is a good sign and perhaps the first of many such news articles linking PRR with DNDN's success!!

    CHEERS
    BIRDSEYE



    FDA Approval For Dendreon Provenge Immunotherapy Vaccine
    Published: 30-Apr-2010.


    Nasdaq-listed company Dendreon has received approval from FDA to commence sales of its Provenge immunotherapy vaccine for the treatment of prostate cancer.

    Dendreon plans to have three plants to make Provenge by mid of 2011. According to an estimate by Bloomberg the drug is expected to generate $1.2bn by 2014.

    Dendreon is using cancer immunotherapies that use the patient's own immune system to treat cancer and the approval of Provenge represents a scientific and clinical advancement for the treatment of prostate cancer.

    Prima BioMed, an Australian biotechnology firm focused on cancer immunotherapy, is using the technology to develop its CVac immunotherapy cancer vaccine for the treatment of ovarian cancer.

    Prima BioMed said that the approval of Provenge represents a transformational event in the development of cancer treatments and is expected to create a new treatment paradigm for patients with cancer.

    source: http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda_approval_for_dendreon_provenge_immunotherapy_vaccine_100430/
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
34.0¢
Change
0.005(1.49%)
Mkt cap ! $493.8M
Open High Low Value Volume
33.5¢ 34.0¢ 33.0¢ $1.220M 3.642M

Buyers (Bids)

No. Vol. Price($)
3 57289 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
34.0¢ 52306 3
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.